###begin article-title 0
###xml 29 36 29 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a</italic>
###xml 41 49 41 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-16-1</italic>
###xml 53 61 <span type="species:ncbi:9606">Patients</span>
Investigating the Targets of MIR-15a and MIR-16-1 in Patients with Chronic Lymphocytic Leukemia (CLL)
###end article-title 0
###begin p 1
Conceived and designed the experiments: LWH. Performed the experiments: KH. Analyzed the data: KH. Contributed reagents/materials/analysis tools: CR LWH. Wrote the paper: KH LWH.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 169 181 169 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 136 141 <span type="species:ncbi:9606">human</span>
###xml 246 254 <span type="species:ncbi:9606">patients</span>
MicroRNAs (miRNAs) are short, noncoding RNAs that regulate the expression of multiple target genes. Deregulation of miRNAs is common in human tumorigenesis. The miRNAs, MIR-15a/16-1, at chromosome band 13q14 are down-regulated in the majority of patients with chronic lymphocytic leukaemia (CLL).
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 35 47 35 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 82 94 82 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 257 269 257 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 302 303 302 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 311 316 311 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAZ2A</italic>
###xml 321 326 321 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNF41</italic>
###xml 387 399 387 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASSF5, MKK3</italic>
###xml 404 409 404 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRIG1</italic>
###xml 495 507 495 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 115 123 <span type="species:ncbi:9606">patients</span>
###xml 199 207 <span type="species:ncbi:9606">patients</span>
###xml 466 474 <span type="species:ncbi:9606">patients</span>
We have measured the expression of MIR-15a/16-1, and 92 computationally-predicted MIR-15a/16-1 target genes in CLL patients and in normal controls. We identified 35 genes that are deregulated in CLL patients, 5 of which appear to be specific targets of the MIR-15a/16-1 cluster. These targets included 2 genes (BAZ2A and RNF41) that were significantly up-regulated (p<0.05) and 3 genes (RASSF5, MKK3 and LRIG1) that were significantly down-regulated (p<0.05) in CLL patients with down-regulated MIR-15a/16-1 expression.
###end p 5
###begin title 6
Significance
###end title 6
###begin p 7
###xml 46 58 46 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
The genes identified here as being subject to MIR-15a/16-1 regulation could represent direct or indirect targets of these miRNAs. Many of these are good biological candidates for involvement in tumorigenesis and as such, may be important in the aetiology of CLL.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 171 174 171 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Rozman1">[1]</xref>
###xml 289 292 289 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Dohner1">[2]</xref>
###xml 513 516 513 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Dohner1">[2]</xref>
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the Western world. It is a heterogeneous disease associated with a highly variable clinical course [1]. A key feature of CLL is cytogenetic instability, with chromosomal abnormalities occurring in around 80% of cases [2]. While the molecular aetiology of CLL remains largely undetermined, specific recurrent chromosomal aberrations have been well described and serve as independent prognostic indicators for disease progression and survival [2].
###end p 9
###begin p 10
###xml 122 125 122 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Dohner1">[2]</xref>
###xml 223 226 223 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Facon1">[3]</xref>
###xml 227 230 227 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-SchladeBartusiak1">[5]</xref>
###xml 427 430 427 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Bullrich1">[6]</xref>
###xml 432 435 432 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Zojer1">[7]</xref>
###xml 624 627 624 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Liu1">[8]</xref>
###xml 628 632 628 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Migliazza1">[10]</xref>
###xml 113 121 <span type="species:ncbi:9606">patients</span>
Deletion of chromosome 13q is the most frequent chromosomal aberration in CLL, occurring in approximately 50% of patients [2]. The deletion of chromosome band 13q14 has also been reported in a variety of other malignancies [3]-[5], demonstrating the importance of this region in tumorigenesis. There has been wide speculation that the 13q14 region harbours tumour suppressor gene(s) involved in the aetiology of these diseases [6], [7]. Various candidate tumour suppressor genes within the minimal deleted region (MDR) at 13q14 have been investigated, yet studies have consistently failed to detect any pathogenic mutations [8]-[10]. There remains, therefore, a need to identify alternative mechanisms that may influence the development of CLL.
###end p 10
###begin p 11
###xml 88 92 88 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Calin1">[11]</xref>
###xml 93 97 93 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Fabbri2">[15]</xref>
###xml 252 256 252 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Doench1">[16]</xref>
###xml 372 376 372 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Pillai1">[17]</xref>
###xml 377 381 377 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Lim1">[19]</xref>
###xml 515 519 515 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Calin2">[20]</xref>
###xml 429 434 <span type="species:ncbi:9606">human</span>
There is increasing evidence for the involvement of microRNAs (miRNAs) in tumorigenesis [11]-[15]. MicroRNAs are small, non-coding RNAs that mediate the expression of target genes through sequence-specific base pairing with target messenger RNA (mRNA) [16]. Target gene expression is regulated by the degradation of the mRNA or more commonly, through blocking translation [17]-[19]. Deregulation of miRNAs has been implicated in human tumorigenesis and many miRNAs are located in genomic regions involved in cancer [20].
###end p 11
###begin p 12
###xml 12 19 12 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a</italic>
###xml 24 32 24 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-16-1</italic>
###xml 131 135 131 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Calin3">[21]</xref>
###xml 225 229 225 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL2</italic>
###xml 229 233 229 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Cimmino1">[22]</xref>
###xml 263 275 263 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 362 366 362 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Fulci1">[23]</xref>
###xml 113 121 <span type="species:ncbi:9606">patients</span>
Two miRNAs, MIR-15a and MIR-16-1, are located at chromosome band 13q14 and are down-regulated in the majority of patients with CLL [21]. These genes induce apoptosis through the negative regulation of the anti-apoptotic gene BCL2[22]. As such, down-regulation of MIR-15a/16-1 has been associated with the pathogenesis of CLL, although this remains controversial [23].
###end p 12
###begin p 13
###xml 76 80 76 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Lim1">[19]</xref>
###xml 112 124 112 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 174 178 174 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL2</italic>
###xml 312 324 312 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 359 363 359 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Calin4">[24]</xref>
###xml 466 478 466 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
Each miRNA has the potential to mediate the expression of many target genes [19]. It is therefore possible that MIR-15a/16-1 may regulate the expression of genes, other than BCL2, which may be important in the development of CLL. Indeed, a recent study combining experimental and bioinformatic data identified a MIR-15a/16-1 gene signature in leukaemic cells [24]. The aim of this study was to examine the expression patterns of computationally-predicted targets of MIR-15a/16-1 to identify further novel candidate genes involved in the aetiology of CLL.
###end p 13
###begin title 14
Materials and Methods
###end title 14
###begin title 15
Ethics Statement
###end title 15
###begin p 16
###xml 97 105 <span type="species:ncbi:9606">patients</span>
Ethical approval was granted by the North and East Devon Local Research Ethics Committee and all patients provided written informed consent in accordance with the Declaration of Helsinki.
###end p 16
###begin title 17
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 17
###begin p 18
###xml 258 262 258 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-MllerHermelink1">[25]</xref>
###xml 320 321 320 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sup>
###xml 371 375 371 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Matutes1">[26]</xref>
###xml 592 599 592 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 9 17 <span type="species:ncbi:9606">patients</span>
###xml 139 146 <span type="species:ncbi:9606">patient</span>
###xml 264 272 <span type="species:ncbi:9606">Patients</span>
###xml 393 401 <span type="species:ncbi:9606">patients</span>
###xml 501 509 <span type="species:ncbi:9606">patients</span>
Thirteen patients with CLL under the care of the Haematology Unit at the Royal Devon and Exeter Hospital were enrolled in this study. Each patient had an established diagnosis of CLL based on current World Health Organization (WHO) classification guidelines [25]. Patients had a history of persistent lymphocytosis >5x109/l and an immunophenotypic profile typical of CLL [26]. The majority of patients (12/13) had received treatment for their disease prior to involvement in this study. Of the 13 CLL patients included in this study, 7 (54%) had a deletion at 13q14 confirmed by fluorescence in situ hybridisation (FISH) and multiplex ligation-dependent probe amplification (MLPA) (data not shown). Five normal control samples from healthy volunteers were also obtained for this study.
###end p 18
###begin title 19
RNA Extraction
###end title 19
###begin p 20
Total RNA was extracted from whole blood using the MirVana miRNA Isolation kit (Ambion/Applied Biosystems, Foster City, USA), according to the manufacturer's instructions. RNA concentrations were measured using a ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, USA).
###end p 20
###begin title 21
MicroRNA-15a/16-1Expression
###end title 21
###begin p 22
###xml 0 17 0 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MicroRNA-15a/16-1</italic>
###xml 288 292 288 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Chen1">[27]</xref>
###xml 388 393 388 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miRNA</italic>
###xml 446 450 446 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GUSB</italic>
###xml 484 489 484 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miRNA</italic>
###xml 553 557 553 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-AppliedBiosystems1">[28]</xref>
###xml 574 586 574 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR-15a/16-1</italic>
###xml 683 690 681 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a</italic>
###xml 694 702 692 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-16-1</italic>
###xml 734 741 732 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a</italic>
###xml 746 754 744 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-16-1</italic>
###xml 605 613 <span type="species:ncbi:9606">patients</span>
MicroRNA-15a/16-1 expression was determined for each sample using the TaqMan MicroRNA assays kit (Applied Biosystems, Foster City, USA), according to the manufacturer's instructions. The protocol involves real-time quantification of microRNAs by stem-loop RT-PCR, as previously described [27]. All PCR reactions were performed in triplicate. Crossing points (Ct) were determined for each miRNA and an endogenous control gene (beta glucorinidase (GUSB). The relative abundance of each miRNA transcript was then determined using the comparative Ct method [28]. Down-regulated miR-15a/16-1 expression in CLL patients was defined as a >/=50% reduction in the expression levels of either MIR-15a or MIR-16-1 when compared with the average MIR-15a and MIR-16-1 expression levels in the normal control subjects.
###end p 22
###begin title 23
Tiled Low Density Array (TLDA) Analysis
###end title 23
###begin title 24
Reverse Transcription
###end title 24
###begin p 25
###xml 234 238 226 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GUSB</italic>
###xml 859 863 807 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GUSB</italic>
Total RNA (1 microg) was reversed transcribed in 50 microl reactions using the TaqMan Reverse Transcription kit (Applied Biosystems, Foster City, USA), according to the manufacturer's instructions. PCR amplification of the endogenous GUSB gene was performed to ensure that the resulting cDNA samples were of adequate quality. PCR reactions were performed in triplicate on the ABI 7900HT Prism (Applied Biosystems, Foster City, USA). Probe and primer sequences are available on request. Each 25 microl reaction included 5 microl universal master mix, (no AMPerase) (Applied Biosystems, Foster City USA), 5.0 microM probe, 20 microM each primer and 2 microl of cDNA. PCR cycles were 50degreesC for 2 minutes, 95degreesC for 10 minutes followed by 60 cycles of 95degreesC for 15 seconds and 60degreesC for 1 minute. The cDNA was considered adequate quality when GUSB amplification was observed in all three reactions with minimal difference between crossing points.
###end p 25
###begin title 26
TLDA
###end title 26
###begin p 27
TLDA allows for the simultaneous detection of the expression of 384 genes per card. In the present study, TLDA cards were configured into four identical 96-gene sets, allowing two samples to be run in duplicate per card.
###end p 27
###begin p 28
###xml 25 36 25 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TargetScanS</italic>
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PicTar</italic>
###xml 96 108 96 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 142 153 142 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TargetScanS</italic>
###xml 349 353 349 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Lewis1">[29]</xref>
###xml 361 367 361 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PicTar</italic>
###xml 497 501 497 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Krek1">[30]</xref>
###xml 640 652 640 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 687 698 687 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TargetScanS</italic>
###xml 703 709 703 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pictar</italic>
###xml 980 992 980 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 1035 1038 1035 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">18S</italic>
###xml 1040 1044 1040 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACTB</italic>
###xml 1046 1050 1046 1050 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GUSB</italic>
###xml 1055 1058 1055 1058 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B2M</italic>
The web-based programmes TargetScanS () and PicTar () were used to predict potential targets of MIR-15a/16-1 for inclusion on the TLDA cards. TargetScanS predicts biological targets of miRNAs by searching for the presence of conserved 8mer and 7mer sites that match the seed region (nucleotides 2-7 at the 5' end segment of the MIRNA) of each miRNA [29], while PicTar is a sophisticated algorithm that predicts miRNA targets by searching for pair-wise alignments that are conserved across species [30]. Genes were selected for inclusion on the TLDA cards if the following criteria were satisfied: (1) the genes were predicted as targets of MIR-15a/16-1 by both computational programmes (TargetScanS and Pictar), and (2) Searches with Pubmed showed good biological evidence for potential involvement in tumorigenesis (Eg. proto-oncogenes, tumour-suppressor genes, transcription factors or genes involved in cell cycle regulation). Each 96-gene set included 92 predicted targets of MIR-15a/16-1 as well as four endogenous control genes; 18S, ACTB, GUSB and B2M.
###end p 28
###begin p 29
###xml 187 188 175 176 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 9 16 <span type="species:ncbi:9606">patient</span>
###xml 787 794 <span type="species:ncbi:9606">patient</span>
For each patient sample, a reaction mix of 400 microl was prepared, including 200 microl 2x TaqMan universal master mix (no AMPerase) (Applied Biosystems, Foster City, USA), 160 microl dH2O and 40 microl cDNA template. Aliquots (100 microl) of the reaction mix were added to the appropriate sample loading ports on the TLDA card. The cards were centrifuged twice for 1 minute at 12,000 rpm to allow distribution of the reaction mix to each of the reaction wells. PCR amplifications were performed on the ABI 7900HT platform (Applied Biosystems, Foster City, USA). Cycling conditions were 50degreesC for 2 minutes, 94.5degreesC for 10 minutes followed by 40 cycles of 97degreesC for 30 seconds and 57.9degreesC for 1 minute. The expression of each gene was measured in duplicate for each patient.
###end p 29
###begin title 30
Analysis of gene expression
###end title 30
###begin p 31
###xml 440 444 432 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">test</sup>
###xml 521 524 513 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">18S</italic>
###xml 526 530 518 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACTB</italic>
###xml 532 536 524 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GUSB</italic>
###xml 541 544 533 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B2M</italic>
###xml 549 554 541 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AveEC</sup>
###xml 716 729 708 713 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;&#916;&#916;Ct</sup>
###xml 729 733 713 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-AppliedBiosystems1">[28]</xref>
###xml 820 824 788 792 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">test</sup>
###xml 907 911 875 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL2</italic>
###xml 939 942 903 906 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ref</sup>
The abundance of each transcript in the TLDA analysis is directly proportional to the point in the reaction where the signal appears above the background fluorescence levels. This is termed the crossing point (Ct). Differences in the abundance of two targets are therefore directly proportional to the differences in their crossing points (DeltaCt). We calculated the difference between the crossing point (DeltaCt) for each test target (Cttest) compared with the average crossing point of four endogenous control genes (18S, ACTB, GUSB and B2M) (CtAveEC) in each sample. The level of each transcript relative to that of the endogenous control levels for any given sample could then be calculated from the equation 2-DeltaDeltaCt[28] where DeltaDeltaCt is the DeltaCt value of the test transcript in that sample (DeltaCttest) normalised to a reference transcript which was taken to be the average levels of BCL2 in normal controls (DeltaCtref).
###end p 31
###begin title 32
Gene Ontology Analysis
###end title 32
###begin p 33
###xml 85 93 <span type="species:ncbi:9606">patients</span>
The Gene Ontology (GO) categories of genes that were differentially expressed in CLL patients and normal controls were analysed with the 'PANTHER Classification System' GO browser tool. ().
###end p 33
###begin title 34
Analysis of Adenylate Uridylate-Rich Elements (ARE)
###end title 34
###begin p 35
###xml 27 39 27 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
Deregulated targets of the MIR-15a/16-1 cluster were analysed for the presence of AU-rich elements which have been reported to mediate mRNA stability (ref). Analysis was performed using the ARE-mRNA database version 3.0 (ARED; ).
###end p 35
###begin title 36
Protein Expression Analysis
###end title 36
###begin p 37
###xml 60 72 60 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 125 130 <span type="species:ncbi:9606">Human</span>
Where possible, protein expression analysis of the putative MIR-15a/16-1 target genes in CLL was investigated using the 'The Human Protein Atlas' bioinformatics tool ().
###end p 37
###begin title 38
Statistical Analysis
###end title 38
###begin p 39
###xml 142 149 <span type="species:ncbi:9606">patient</span>
Statistical analysis was performed using SPSS 11.0 (SPSS, Inc., Chicago, IL, USA). The comparison of target gene expression between different patient groups was performed using the Mann-Whitney U test. A P value of <0.05 was considered statistically significant.
###end p 39
###begin title 40
Results
###end title 40
###begin title 41
MicroRNA-15a/16-1Expression
###end title 41
###begin p 42
###xml 0 17 0 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MicroRNA-15a/16-1</italic>
###xml 200 212 200 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 263 270 263 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007169-t001">Table 1</xref>
###xml 324 336 324 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 71 79 <span type="species:ncbi:9606">patients</span>
###xml 109 116 <span type="species:ncbi:9606">patient</span>
MicroRNA-15a/16-1 expression was down-regulated in the majority of CLL patients (10/13, 77%), including each patient with an identified deletion at 13q14. In the majority of cases, down-regulation of MIR-15a/16-1 correlated with chromosome 13q14 deletion status (Table 1), but in three cases (CLL 03, CLL 11 and CLL 13) the MIR-15a/16-1 cluster was down-regulated in the absence of an identifiable 13q14 deletion.
###end p 42
###begin title 43
###xml 11 28 11 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MicroRNA-15a/16-1</italic>
Summary of MicroRNA-15a/16-1 expression levels and chromosome band 13q14 deletion status.
###end title 43
###begin p 44
Discrepancies are highlighted in bold.
###end p 44
###begin title 45
Assessment of Sample Quality for TLDA Analysis
###end title 45
###begin p 46
###xml 79 83 79 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GUSB</italic>
RNA was extracted and reverse transcribed for all subjects as described above. GUSB was successfully amplified in triplicate in all 18 cases (data not shown), indicating that the cDNA was of adequate quality to perform TLDA analysis.
###end p 46
###begin title 47
Micro RNA Target Prediction
###end title 47
###begin p 48
###xml 89 100 89 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TargetScanS</italic>
###xml 105 111 105 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PicTar</italic>
###xml 117 124 117 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a</italic>
###xml 129 137 129 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-16-1</italic>
A total of 99 and 145 potential gene targets were predicted by the web-based programmes (TargetScanS and PicTar) for MIR-15a and MIR-16-1 respectively. Of these putative targets, 92 genes with a high likelihood for involvement in tumorigenesis were selected for inclusion on the TLDA cards.
###end p 48
###begin title 49
###xml 34 42 <span type="species:ncbi:9606">patients</span>
Differentially expressed genes in patients with CLL and Normal Controls
###end title 49
###begin p 50
###xml 297 305 297 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007169-g001">Figure 1</xref>
###xml 157 164 <span type="species:ncbi:9606">patient</span>
###xml 287 295 <span type="species:ncbi:9606">patients</span>
###xml 390 398 <span type="species:ncbi:9606">patients</span>
Real-time PCR amplification detected the expression of 80/92 (87%) target genes and all four endogenous control genes in both the CLL and the normal control patient cohorts. TLDA analysis identified 35 genes that were differentially expressed (p<0.05) between the CLL and normal control patients (Figure 1). Of these genes, 27 (77%) were up-regulated and 8 (23%) were down-regulated in the patients with CLL compared with the normal controls.
###end p 50
###begin title 51
###xml 34 42 <span type="species:ncbi:9606">patients</span>
Differentially expressed genes in patients with CLL and normal controls.
###end title 51
###begin p 52
###xml 73 81 <span type="species:ncbi:9606">patients</span>
###xml 111 119 <span type="species:ncbi:9606">patients</span>
###xml 216 224 <span type="species:ncbi:9606">patients</span>
###xml 350 358 <span type="species:ncbi:9606">patients</span>
Bar graph representing the difference in relative gene expression in CLL patients compared with normal control patients. The dark grey bars above the x-axis represent genes that are significantly up-regulated in CLL patients compared with normal controls. Light grey bars below the x-axis represent genes that are significantly down-regulated in CLL patients when compared to normal controls. P-values; * represents <0.05, and ** represents <0.01
###end p 52
###begin p 53
###xml 52 60 <span type="species:ncbi:9606">patients</span>
The GO of the differentially expressed genes in CLL patients and normal controls was assessed with the 'PANTHER Classification System' (). The most frequently represented GO categories included: (1) transcription factor, (2) cell cycle and (3) signal transduction. Other significant GO categories represented included; apoptosis, inhibition of apoptosis, nucleic acid metabolism, regulatory molecule and kinase.
###end p 53
###begin title 54
Genes specifically deregulated by the down-regulation of the MIR-15a/16-1 cluster
###end title 54
###begin p 55
###xml 132 144 132 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 200 205 200 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAZ2A</italic>
###xml 210 215 210 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNF41</italic>
###xml 236 244 236 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007169-g002">Figure 2</xref>
###xml 253 266 253 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASSF5, MKK3,</italic>
###xml 271 276 271 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRIG1</italic>
###xml 299 307 299 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007169-g003">Figure 3</xref>
###xml 344 356 344 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 382 394 382 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 551 556 551 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAZ2A</italic>
###xml 558 563 558 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNF41</italic>
###xml 568 573 568 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRIG1</italic>
###xml 316 324 <span type="species:ncbi:9606">patients</span>
Of the 92 gene targets assessed, TLDA analysis identified 5 (5%) that may be specifically deregulated by the down-regulation of the MIR-15a/16-1 cluster. Of these 5 differentially expressed genes, 2 (BAZ2A and RNF41) were up-regulated (Figure 2) and 3 (RASSF5, MKK3, and LRIG1) were down-regulated (Figure 3) in CLL patients with low levels of MIR-15a/16-1 expression. The putative MIR-15a/16-1 targets were investigated for the presence of AU-rich elements, which have been implicated in regulation of mRNA stability. Of the 5 identified targets, 3 (BAZ2A, RNF41 and LRIG1) contained AREs in their 3' UTR.
###end p 55
###begin title 56
###xml 69 81 69 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR-15a/16-1</italic>
###xml 40 48 <span type="species:ncbi:9606">patients</span>
Significantly up-regulated genes in CLL patients with down-regulated miR-15a/16-1 expression.
###end title 56
###begin p 57
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAZ2A</italic>
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNF41</italic>
###xml 116 128 116 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR-15a/16-1</italic>
###xml 179 191 179 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR-15a/16-1</italic>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
###xml 158 166 <span type="species:ncbi:9606">patients</span>
Boxplot graphs representing the relative up-regulation of genes BAZ2A and RNF41 in CLL patients with down-regulated miR-15a/16-1 expression compared with CLL patients with normal miR-15a/16-1 expression.
###end p 57
###begin title 58
###xml 71 83 71 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR-15a/16-1</italic>
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Significantly down-regulated genes in CLL patients with down-regulated miR-15a/16-1 expression.
###end title 58
###begin p 59
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASSF5</italic>
###xml 74 78 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MKK3</italic>
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRIG1</italic>
###xml 125 137 125 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR-15a/16-1</italic>
###xml 188 200 188 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">miR-15a/16-1</italic>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 167 175 <span type="species:ncbi:9606">patients</span>
Boxplot graphs representing the relative down-regulation of genes RASSF5, MKK3 and LRIG1 in CLL patients with down-regulated miR-15a/16-1 expression compared with CLL patients with normal miR-15a/16-1 expression.
###end p 59
###begin title 60
Protein expression analysis of the putative MIR-15a/16-1 target genes
###end title 60
###begin p 61
###xml 96 101 96 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNF41</italic>
###xml 106 110 106 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MKK3</italic>
###xml 165 170 165 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNF41</italic>
###xml 259 264 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNF41</italic>
###xml 398 402 398 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MKK3</italic>
###xml 590 595 590 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAZ2A</italic>
###xml 597 603 597 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASSF5</italic>
###xml 608 613 608 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRIG1</italic>
###xml 34 39 <span type="species:ncbi:9606">Human</span>
Protein expression data from 'The Human Protein Atlas' () bioinformatics tool was available for RNF41 and MKK3. This data provided evidence for the up-regulation of RNF41 in B-CLL, since immunohistochemistry analysis demonstrated weak-moderated expression of RNF41 in B-CLL samples, while peripheral blood mononuclear cells from healthy blood donors showed negative-weak expression of the protein. MKK3 protein expression data showed that malignant lymphoma tissues typically exhibited weak cytoplasmic immunoreactivity or were negative. Protein expression analysis in CLL subjects for the BAZ2A, RASSF5 and LRIG1 genes is currently unavailable and represents an interesting area for future research.
###end p 61
###begin title 62
Discussion
###end title 62
###begin p 63
###xml 88 100 88 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 331 343 331 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
###xml 228 236 <span type="species:ncbi:9606">patients</span>
We have investigated the expression patterns of 92 computationally-predicted targets of MIR-15a/16-1 in 13 patients with CLL and 5 normal controls using TLDA analysis. We identified 35 genes that are differentially regulated in patients with CLL compared with normal controls and 5 genes which may be specifically regulated by the MIR-15a/16-1 cluster at chromosome band 13q14. These genes may be important in the aetiology of CLL and as such, provide interesting targets for future studies.
###end p 63
###begin p 64
###xml 122 130 122 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007169-g001">Figure 1</xref>
###xml 427 439 427 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 47 55 <span type="species:ncbi:9606">patients</span>
###xml 190 197 <span type="species:ncbi:9606">patient</span>
A comparison of the expression profiles of CLL patients and normal controls identified 35 differentially regulated genes (Figure 1), the majority of which (77%) were up-regulated in the CLL patient group. Gene ontology analysis demonstrated that many of the differentially regulated genes were transcription factors, cell cycle-related genes or genes involved in signal transduction. Although not specifically regulated by the MIR-15a/16-1 cluster, these deregulated genes may represent important contributors to the process of leukaemogenesis.
###end p 64
###begin p 65
###xml 38 50 38 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 71 72 71 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 80 85 80 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAZ2A</italic>
###xml 90 95 90 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNF41</italic>
###xml 159 171 159 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 184 192 184 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007169-g002">Figure 2</xref>
###xml 254 266 254 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 465 471 465 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASSF5</italic>
###xml 473 477 473 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MKK3</italic>
###xml 482 487 482 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRIG1</italic>
###xml 570 582 570 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 595 603 595 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007169-g003">Figure 3</xref>
###xml 645 657 645 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 754 766 754 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
###xml 541 549 <span type="species:ncbi:9606">patients</span>
The 5 genes specifically regulated by MIR-15a/16-1 expression included 2 genes (BAZ2A and RNF41) that were significantly up-regulated in CLL patients with low MIR-15a/16-1 expression (Figure 2). These genes may represent direct biological targets of the MIR-15a/16-1 cluster. Further experimental work including luciferase reporter gene assays or mutagenesis of predicted miRNA binding sites may be useful to examine these possibilities further. A further 3 genes (RASSF5, MKK3 and LRIG1) were expressed at significantly lower levels in CLL patients with down-regulated MIR-15a/16-1 expression (Figure 3). These genes may be indirect targets of MIR-15a/16-1, their expression perhaps being repressed by another, as yet unidentified, direct target of the MIR-15a/16-1 cluster.
###end p 65
###begin p 66
###xml 170 175 170 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNF41</italic>
###xml 233 237 233 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MKK3</italic>
###xml 346 358 346 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
Further evidence for the deregulation of the target genes we identified in CLL was obtained from protein expression data (). This analysis confirmed the up-regulation of RNF41 in B-CLL subjects. It also demonstrated weak or negative MKK3 protein expression in malignant lymphoma tissues, consistent with our data. The functions of the identified MIR-15a/16-1 target genes are discussed further below. Protein data were not available for the remaining three targets we identified. This represents an interesting area for future work.
###end p 66
###begin p 67
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAZ2A</italic>
###xml 127 131 127 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Jones1">[31]</xref>
###xml 246 251 246 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAZ2A</italic>
###xml 429 432 429 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ETV</italic>
###xml 462 467 462 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAZ2A</italic>
###xml 467 471 467 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Panagopoulos1">[32]</xref>
###xml 552 557 552 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAZ2A</italic>
###xml 603 607 603 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Panagopoulos1">[32]</xref>
BAZ2A is a member of the bromodomain family of genes which function as integral components of chromatin re-modelling complexes [31]. They are believed to play a role in the chromatin-dependent regulation of transcription. Interestingly, putative BAZ2A deregulation has been implicated in a paediatric case of pre-B acute lymphoblastic leukemia (ALL) in which a cryptic rearrangement between 12p13 and 12q13 generated a fusion of ETV with an intronic sequence of BAZ2A[32]. The authors do acknowledge, however, that the leukaemogenic impact of putative BAZ2A deregulation remains undetermined at present [32].
###end p 67
###begin p 68
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNF41</italic>
###xml 105 110 105 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNF41</italic>
###xml 171 175 171 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Abdullah1">[33]</xref>
###xml 346 350 346 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Abdullah1">[33]</xref>
###xml 465 469 465 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Abdullah1">[33]</xref>
###xml 553 557 553 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Abdullah1">[33]</xref>
###xml 611 616 611 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNF41</italic>
###xml 822 826 822 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Jing1">[34]</xref>
###xml 856 861 856 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNF41</italic>
###xml 910 914 910 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Jing1">[34]</xref>
###xml 1023 1028 1023 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RNF41</italic>
###xml 622 628 <span type="species:ncbi:10090">murine</span>
RNF41 is an evolutionarily conserved RING finger-containing ubiquitin ligase It has been speculated that RNF41 is involved in the aetiology of haematological malignancies [33]. The gene resides at chromosome band 12q13, a locus that frequently demonstrates aberrations associated with acute myeloid leukemia (AML) or non-Hodgkin's lymphoma (NHL) [33]. Additionally, the gene is differentially expressed in foetal and adult haematopoietic stem cells and progenitors [33], suggesting that it may be involved in cell lineage commitment and differentiation [33]. A recent study demonstrated that over-expression of RNF41 in a murine multipotent haematopoietic progenitor cell line (EML) attenuated erythroid and myeloid differentiation in response to the cytokines erythropoietin (EPO), interleukin-3 (IL-3) and retinoic acid [34]. This response resulted from RNF41-specific regulation of cytokine receptor levels [34]. Further studies are required to determine whether other haematopoietic cytokine receptors are regulated by RNF41 and whether the gene additionally influences haematopoietic progenitor cell differentiation into lymphoid lineages.
###end p 68
###begin p 69
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASSF5</italic>
###xml 180 184 180 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Geli1">[35]</xref>
###xml 292 296 292 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Vos1">[36]</xref>
###xml 298 302 298 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Aoyama1">[37]</xref>
###xml 439 443 439 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Guil1">[38]</xref>
###xml 238 243 <span type="species:ncbi:9606">human</span>
RASSF5 is a member of the RAS association domain family. It can act as a tumour suppressor by inducing apoptosis and delaying cell cycle progression in different cancer cell lines [35]. The gene is epigenetically silenced in a variety of human cancers by CpG island promoter hypermethylation [36], [37]. Interestingly, miRNAs can themselves act as epigenetic modifiers by the post-transcriptional regulation of chromatin modifying enzymes [38].
###end p 69
###begin p 70
###xml 339 343 339 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Davis1">[39]</xref>
###xml 345 349 345 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MKK3</italic>
###xml 482 486 482 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MKK3</italic>
###xml 582 586 582 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Ringshausen1">[40]</xref>
###xml 696 700 696 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Ringshausen1">[40]</xref>
###xml 861 865 861 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Molica1">[41]</xref>
###xml 918 922 918 922 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MKK3</italic>
###xml 970 982 970 982 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 1070 1082 1070 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 1139 1142 1139 1142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Dohner1">[2]</xref>
###xml 843 851 <span type="species:ncbi:9606">patients</span>
###xml 941 949 <span type="species:ncbi:9606">patients</span>
###xml 1012 1020 <span type="species:ncbi:9606">patients</span>
The mitogen-activated protein (MAP) kinase pathways mediate the transduction of extracellular signals via protein phosporylation cascades. Three distinct MAP kinase pathways have been defined; (1) extracellular-signal-related kinases (ERKs), (2) the c-Jun N-terminal kinases (JNKs) and (3) p38 stress-activated protein kinases (p38 MAPKs) [39]. MKK3 is one of the upstream activator kinases for the p38 MAPK pathway. A recent study demonstrated that the p38 MAPK pathway, including MKK3, is constitutively activated in B-CLL cells but not their normal peripheral B-cell counterpart [40]. The constitutive p38 MAPK pathway activation results in up-regulation of matrix metalloproteinase-9 (MMP-9) [40], a critical factor in tumour angiogenesis and tumour homing. Elevated serum levels of MMP-9 are associated with an unfavourable prognosis for patients with CLL [41]. Our study identified significantly lower levels of MKK3 expression in CLL patients with down-regulated MIR-15a/16-1. This is consistent with CLL patients harbouring chromosome 13q14 deletions, and hence MIR-15a/16-1 down-regulation, displaying a more favourable prognosis [2].
###end p 70
###begin p 71
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRIG1</italic>
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRIG</italic>
###xml 180 184 180 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Nilsson1">[42]</xref>
###xml 186 191 186 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRIG1</italic>
###xml 280 284 280 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Laederich1">[43]</xref>
###xml 459 464 459 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRIG1</italic>
###xml 621 626 621 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRIG1</italic>
###xml 689 693 689 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Hedman1">[44]</xref>
###xml 798 803 798 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRIG1</italic>
###xml 898 902 898 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Hedman2">[45]</xref>
###xml 922 927 922 927 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRIG1</italic>
###xml 1056 1060 1056 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Hedman2">[45]</xref>
###xml 1123 1127 1123 1127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRIG</italic>
###xml 1183 1188 1183 1188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRIG1</italic>
###xml 592 597 <span type="species:ncbi:9606">human</span>
###xml 1206 1211 <span type="species:ncbi:9606">human</span>
LRIG1 is a member of a family of LRIG genes that encode integral membrane proteins with extracellular/lumenal extensions consisting of leucine-rich and immuloglobulin-like domains [42]. LRIG1 interacts with the ErbB receptor tyrosine kinase to negatively regulate EGFR signalling [43]. This regulation is mediated through the recruitment of E3 ubiquitin ligases, resulting in ubiquitinylation, internalisation and lysosomal degradation of the ErbB receptors. LRIG1 is a proposed tumour suppressor gene. It localizes at chromosome band 3p14.3, a chromosomal region that is commonly deleted in human cancers. Additionally, LRIG1 is down-regulated in a variety of different tumour cell lines [44] consistent with it being a tumour suppressor gene. It has been hypothesised that the down-regulation of LRIG1 could unleash EGFR signalling which may contribute to the development of various malignancies [45]. Of note, however, LRIG1 expression is up-regulated in some tumours, suggesting that the gene functions as a tumour promoter under certain circumstances [45]. Further studies are required to unravel the functions of the LRIG proteins and to further understand the contribution of LRIG1 dysregulation to human tumorigenesis.
###end p 71
###begin p 72
###xml 167 179 167 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 724 735 724 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TargetScanS</italic>
###xml 740 746 740 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PicTar</italic>
###xml 832 836 820 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Bentwich1">[46]</xref>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
The majority (87/92, 95%) of the computationally-predicted targets investigated in this study were not differentially regulated in CLL patients with varying levels of MIR-15a/16-1 expression. A possible explanation for this may be that the analysis was performed on mRNA rather than on proteins. Through imperfect pairing with their target mRNAs, some miRNAs can reduce the protein levels of a target gene with minimal variation of the mRNA levels. Alternatively, the low predictive power of the bioinformatics tools used for miRNA gene target prediction may also have contributed to this finding. Computational algorithms for the prediction of miRNA targets are acknowledged to yield a large number of false-positive hits. TargetScanS and PicTar are estimated to have a 22-31% and approximately30% false-positive rate respectively [46]. Our data suggests that these figures may under-estimate the false-positive rates associated with these programmes. Use of additional bioinformatics programmes, such as miRanda (), in combination may enhance the positive predictive power of these commonly used tools.
###end p 72
###begin p 73
###xml 117 129 117 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 348 360 348 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 436 440 436 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL2</italic>
###xml 478 483 478 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 509 521 509 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 542 546 542 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL2</italic>
###xml 546 550 546 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Cimmino1">[22]</xref>
###xml 601 605 601 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007169-Fulci1">[23]</xref>
###xml 629 633 629 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL2</italic>
###xml 797 809 797 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 1045 1049 1045 1049 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCL2</italic>
###xml 1071 1083 1071 1083 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 674 682 <span type="species:ncbi:9606">patients</span>
###xml 779 787 <span type="species:ncbi:9606">patients</span>
The regulation of gene expression is often complex and multifactoral. The removal of one regulatory element, such as MIR-15a/16-1, may be compensated for by the altered expression of other regulatory elements, thus maintaining the normal expression of the target gene. This may also explain why our study identified so few differentially regulated MIR-15a/16-1 targets. Interestingly, the expression patterns of the anti-apoptotic gene BCL2 may support this hypothesis. Cimmino et al (2005) demonstrated that MIR-15a/16-1 negatively regulate BCL2[22], although this relationship remains controversial [23]. In the current study, BCL2 was significantly over-expressed in CLL patients compared with normal controls (p = 0.001). The anti-apoptotic gene was also up-regulated in CLL patients with low MIR-15a/16-1 expression compared to those with normal expression levels of the miRNAs, however, this did not reach the level of significance (p = 0.161) probably due to the small sample size in this study. Our data indicates that the regulation of BCL2 may be influenced by MIR-15a/16-1 as well as other regulatory elements, exerting a combinatorial effect.
###end p 73
###begin p 74
###xml 105 117 105 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 293 305 293 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIR-15a/16-1</italic>
###xml 121 129 <span type="species:ncbi:9606">patients</span>
###xml 212 220 <span type="species:ncbi:9606">patients</span>
In conclusion, our work has investigated the expression patterns of computationally-predicted targets of MIR-15a/16-1 in patients with CLL using TLDA analysis. We have identified 35 genes that are deregulated in patients with CLL and 5 genes that are specifically deregulated by low levels of MIR-15a/16-1 expression. The identified genes are all good biological candidates for involvement in tumorigenesis and as such, may be important in the aetiology of CLL. They provide interesting candidate genes for future studies and may represent possible targets for therapeutic intervention.
###end p 74
###begin p 75
###xml 81 89 <span type="species:ncbi:9606">patients</span>
The authors would like to thank Abigail Jelfs for carrying out RNA isolation and patients at the Royal Devon and Exeter Hospital for contributing to this study.
###end p 75
###begin title 76
References
###end title 76
###begin article-title 77
Chronic lymphocytic leukemia.
###end article-title 77
###begin article-title 78
Genomic aberrations and survival in chronic lymphocytic leukemia.
###end article-title 78
###begin article-title 79
###xml 132 140 <span type="species:ncbi:9606">patients</span>
Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy.
###end article-title 79
###begin article-title 80
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Molecular delineation of 13q deletion boundaries in 20 patients with myeloid malignancies.
###end article-title 80
###begin article-title 81
Significant involvement of chromosome 13q deletions in progression of larynx cancer, detected by comparative genomic hybridization.
###end article-title 81
###begin article-title 82
Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene.
###end article-title 82
###begin article-title 83
Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization.
###end article-title 83
###begin article-title 84
Cloning of two candidate tumor suppressor genes within a 10 kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia.
###end article-title 84
###begin article-title 85
Cloning and characterization of CLLD6, CLLD7, and CLLD8, novel candidate genes for leukemogenesis at chromosome 13q14, a region commonly deleted in B-cell chronic lymphocytic leukemia.
###end article-title 85
###begin article-title 86
Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia.
###end article-title 86
###begin article-title 87
Investigation of microRNA alterations in leukemias and lymphomas.
###end article-title 87
###begin article-title 88
Oncomirs - microRNAs with a role in cancer.
###end article-title 88
###begin article-title 89
MicroRNA expression and function in cancer.
###end article-title 89
###begin article-title 90
MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications.
###end article-title 90
###begin article-title 91
Regulatory mechanisms of microRNAs involvement in cancer.
###end article-title 91
###begin article-title 92
Specificity of microRNA target selection in translational repression.
###end article-title 92
###begin article-title 93
Repression of protein synthesis by miRNAs: how many mechanisms?
###end article-title 93
###begin article-title 94
MicroRNAs: genomics, biogenesis, mechanism, and function.
###end article-title 94
###begin article-title 95
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs.
###end article-title 95
###begin article-title 96
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.
###end article-title 96
###begin article-title 97
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.
###end article-title 97
###begin article-title 98
miR-15 and miR-16 induce apoptosis by targeting BCL2.
###end article-title 98
###begin article-title 99
Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia.
###end article-title 99
###begin article-title 100
###xml 42 47 <span type="species:ncbi:9606">human</span>
MiR-15a and miR-16-1 cluster functions in human leukemia.
###end article-title 100
###begin article-title 101
Chronic lymphocytic leukaemia/small lymphocytic lymphoma.
###end article-title 101
###begin article-title 102
The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL.
###end article-title 102
###begin article-title 103
Real-time quantification of microRNAs by stem-loop RT-PCR.
###end article-title 103
###begin article-title 104
Relative quantitation of gene expression.
###end article-title 104
###begin article-title 105
###xml 81 86 <span type="species:ncbi:9606">human</span>
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.
###end article-title 105
###begin article-title 106
Combinatorial microRNA target predictions.
###end article-title 106
###begin article-title 107
A novel family of bromodomain genes.
###end article-title 107
###begin article-title 108
Fusion of ETV6 with an intronic sequence of the BAZ2A gene in a paediatric pre-B acute lymphoblastic leukaemia with a cryptic chromosome 12 rearrangement.
###end article-title 108
###begin article-title 109
###xml 88 93 <span type="species:ncbi:10090">mouse</span>
FLRF, a novel evolutionarily conserved RING finger gene, is differentially expressed in mouse fetal and adult hematopoietic stem cells and progenitors.
###end article-title 109
###begin article-title 110
E3 ligase FLRF (Rnf41) regulates differentiation of hematopoietic progenitors by governing steady-state levels of cytokine and retinoic acid receptors.
###end article-title 110
###begin article-title 111
The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma.
###end article-title 111
###begin article-title 112
The pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung.
###end article-title 112
###begin article-title 113
Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases.
###end article-title 113
###begin article-title 114
DNA methylomes, histone codes and miRNAs: Tying it all together.
###end article-title 114
###begin article-title 115
Signal transduction by the JNK group of MAP kinases.
###end article-title 115
###begin article-title 116
Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells.
###end article-title 116
###begin article-title 117
###xml 81 89 <span type="species:ncbi:9606">patients</span>
Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia.
###end article-title 117
###begin article-title 118
###xml 45 50 <span type="species:ncbi:9606">human</span>
Cloning, characterization, and expression of human LIG1.
###end article-title 118
###begin article-title 119
The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.
###end article-title 119
###begin article-title 120
Is LRIG1 a tumour suppressor gene at chromosome 3p14.3?
###end article-title 120
###begin article-title 121
###xml 69 74 <span type="species:ncbi:9606">human</span>
LRIG inhibitors of growth factor signalling - double-edged swords in human cancer?
###end article-title 121
###begin article-title 122
Prediction and validation of microRNAs and their targets.
###end article-title 122
###begin p 123
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 123
###begin p 124
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This study was funded by the Exeter Leukaemia Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 124

